ArticlePloS one2026
Expression of melanoma differentiation-associated gene 5 in the epidermis and cutaneous deposition of complement C3 and immunoglobulins in patients with dermatomyositis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDermatomyositis (DM) is an autoimmune disease characterized by interface dermatitis, but the immunopathological features underlying cutaneous inflammation remain incompletely understood. The aim of this study was to characterize the cutaneous deposition of complement and immunoglobulins, as well as to clarify the localization of melanoma differentiation-associated gene 5 (MDA5) in DM skin.
methodsSkin biopsy specimens from 22 patients with DM and 13 control specimens obtained from cancer-free skin of patients with dermatofibrosarcoma protuberans were examined. Immunohistochemical staining for complement C3c, immunoglobulins (IgG, IgM, and IgA), and MDA5 was semi-quantitatively evaluated, focusing on the superficial dermis near the dermo-epidermal junction.
resultsSignificantly greater deposition of C3c, IgM, and IgA was exhibited by DM skin compared with control skin (all p ≤ 0.001), predominantly localised to the superficial dermis at sites of interface dermatitis. In contrast, IgG showed comparable deposition in both DM and control skin. MDA5 was strongly expressed in the stratum spinosum and basal layer of the epidermis in both DM and control skin. Enhanced MDA5 expression was notably observed in dermal inflammatory cells and capillaries in DM skin, but minimal expression was observed in the dermis of control skin.
conclusionsDM skin is characterized by the deposition of immunoglobulins and complement C3c at sites of interface dermatitis, findings that are consistent with immune complex-mediated injury. MDA5 is widely expressed in both DM and control skin epidermis and can be detected in the infiltrating inflammatory cells of DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.